
Wave Life Sciences Ltd. (NASDAQ:WVE) stock rose Tuesday on continued optimism after the company announced data from the lowest therapeutic cohort of the ongoing INLIGHT trial of WVE-007 for weight loss.
On Monday, the company said that a single 240 mg dose of WVE-007 led to an improvement in body composition characterized by reductions in total and visceral fat mass at three months and an increase in lean mass.